These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11148435)

  • 21. Intraduodenal conjugated bile salts exert negative feedback control on gall bladder emptying in the fasting state without affecting cholecystokinin release or antroduodenal motility.
    van Ooteghem NA; Moschetta A; Rehfeld JF; Samsom M; van Erpecum KJ; van Berge-Henegouwen GP
    Gut; 2002 May; 50(5):669-74. PubMed ID: 11950814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.
    Jonkers IJ; Smelt AH; Ledeboer M; Hollum ME; Biemond I; Kuipers F; Stellaard F; Boverhof R; Meinders AE; Lamers CH; Masclee AA
    Gut; 2003 Jan; 52(1):109-15. PubMed ID: 12477770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fasting gallbladder volume, postprandial emptying and cholecystokinin release in gallstone patients and normal subjects.
    van Erpecum KJ; van Berge Henegouwen GP; Stolk MF; Hopman WP; Jansen JB; Lamers CB
    J Hepatol; 1992 Mar; 14(2-3):194-202. PubMed ID: 1500683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gallstones in acromegalic patients undergoing different treatment regimens.
    Schmidt K; Leuschner M; Harris AG; Althoff PH; Jacobi V; Jungmann E; Schumm-Draeger PM; Rau H; Braulke C; Usadel KH
    Clin Investig; 1992 Jul; 70(7):556-9. PubMed ID: 1356530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prokinetic effect of alpha-adrenergic antagonist, and beta-adrenergic antagonist on gall-bladder motility in humans with gall-stone disease.
    Sengupta S; Modak P; McCauley N; O'Donnell LJ
    Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):581-3. PubMed ID: 17556905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postprandial release of cholecystokinin and pancreatic polypeptide in health and in gallstone disease: relationships with gallbladder contraction.
    Glasbrenner B; Domínguez-Muñoz JE; Nelson DK; Pieramico O; Holzwarth C; Riepl RL; Malfertheiner P
    Am J Gastroenterol; 1994 Mar; 89(3):404-10. PubMed ID: 8122654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment.
    Hopman WP; Van Liessum PA; Pieters GF; Jansen JB; Lamers CB; Smals AG; Rosenbusch G; Kloppenborg PW
    Dig Dis Sci; 1992 Nov; 37(11):1685-90. PubMed ID: 1425066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin receptor subtypes 2 and 5 mediate inhibition of egg yolk-induced gall bladder emptying in mice.
    Kaczmarek P; Singh V; Cashen DE; Yang L; Berk S; Pasternak A; Xiong Y; Shen DM; Hutchins SM; Chapman K; Wiedenmann B; Schaeffer JM; Strowski MZ
    Neurogastroenterol Motil; 2010 Feb; 22(2):204-9, e66. PubMed ID: 19754922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gall bladder emptying in severe idiopathic constipation.
    Penning C; Gielkens HA; Delemarre JB; Lamers CB; Masclee AA
    Gut; 1999 Aug; 45(2):264-8. PubMed ID: 10403740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proceedings of the discussion: 'Tolerability and safety of Sandostatin'.
    Popovic V; Chayvialle JA; Wass JA
    Digestion; 1993; 54 Suppl 1():104-6. PubMed ID: 8359564
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).
    Stewart PM; Stewart SE; Clark PM; Sheppard MC
    Clin Endocrinol (Oxf); 1999 Mar; 50(3):295-9. PubMed ID: 10435053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis--a simultaneous sonographic study.
    Acalovschi M; Dumitraşcu DL; Csakany I
    Gut; 1997 Mar; 40(3):412-7. PubMed ID: 9135534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of growth hormone deficiency and recombinant growth hormone therapy on postprandial gallbladder motility and cholecystokinin release.
    Moschetta A; Twickler TB; Rehfeld JF; van Ooteghem NA; Cabezas MC; Portincasa P; van Berge-Henegouwen GP; van Erpecum KJ
    Dig Dis Sci; 2004 Mar; 49(3):529-34. PubMed ID: 15139510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
    Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.